AstraZeneca Pharma India (506820) Q4 23/24 earnings summary

Executive summary

• Achieved robust growth in FY 2023-24 with total revenue of ₹13,303 million, up 29% year-over-year, and net profit of ₹1,615 million, up 63%.

• Strong performance across key therapy areas: Oncology (+43%), Respiratory & Immunology (+24%), Cardiovascular, Renal & Metabolism (+8%).

• Continued focus on innovation, with nine new medicines and indication approvals, and significant investments in R&D and sustainability.

Financial highlights

• Revenue from operations: ₹12,955 million, up 29% year-over-year.

• Profit before tax: ₹2,195 million, up 64% year-over-year.

• Earnings per share: ₹64.6, up 63% year-over-year.

• Dividend of ₹24 per share recommended for FY 2023-24.

• Net worth increased to ₹7,119 million.

Outlook and guidance

• Ambition to pioneer science, lead in specialist disease areas, and transform patient outcomes in FY 2024-25.

• Continued focus on innovation, operational excellence, and collaboration.

• Plans to expand portfolio in Oncology, CVRM, Respiratory, Immunology, and Rare Diseases.